METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Real-World study tracks new prostate cancer combo in 1,600 men
Disease control OngoingThis study follows about 1,600 men with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus hormone therapy, with or without chemotherapy. Researchers want to see how many men reach very low PSA levels after one year and how the treatment affects their d…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New drug combo shows promise for chinese men with advanced prostate cancer
Disease control OngoingThis study tested whether adding enzalutamide to standard hormone therapy (ADT) helps Chinese men with prostate cancer that has spread and still responds to hormones. 180 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how long i…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma China, Inc. • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New combo therapy aims to slow advanced prostate cancer
Disease control OngoingThis study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer growth in men with metastatic hormone-sensitive prostate cancer. About 223 men will receive darolutamide plus ADT, and their results will be compared to men from an earlier study who r…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
Real-World study pits two prostate cancer drugs Head-to-Head
Knowledge-focused OngoingThis study observes about 500 men with metastatic hormone-sensitive prostate cancer who are already starting treatment with either apalutamide or enzalutamide plus hormone therapy. Researchers will track PSA levels, quality of life, thinking skills, fatigue, and anxiety over time…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Janssen-Cilag Ltd. • Aim: Knowledge-focused
Last updated May 26, 2026 03:16 UTC
-
Canadian prostate cancer study tracks Real-World treatment choices
Knowledge-focused OngoingThis study collects information from medical records of 700 Canadian men with metastatic hormone-sensitive prostate cancer (mHSPC) to see how doctors combine treatments like hormone therapy, newer drugs, and chemotherapy. No new treatments are given—researchers simply observe wha…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 26, 2026 03:06 UTC